Regeneron Pharmaceuticals’ (REGN) second quarter 2014 adjusted earnings (including stock-based compensation expense) of $1.89 per share were well short of the Consensus Estimate of $2.33. The company had earned $1.36 per share in the year-ago quarter. Results were impacted by higher costs. Including one-time items, earnings increased 3.8% to 82 cents per share. A higher…
Avon Products AVP announced on Friday that independent chairman Fred Hassan would be stepping down immediately in light of ” his other professional commitments” (which presently include working as a managing director and partner at private-equity firm Warburg Pincus, as well as a director at Time Warner TWX and chairman of Bausch and Lomb) ….
The outbreak of the deadly and highly infectious Ebola disease in Africa has already claimed multiple lives. According to media reports many health workers including doctors and nurses have also fallen a prey to the worst outbreak of the disease. According to the World Health Organization (WHO), the disease first surfaced in 1976. Among other…
We’re maintaining our fair value estimate and moat rating for Avnet AVT after it reported third-quarter results that indicate trepidation from enterprise businesses in Western markets, but continued growth in emerging markets. Avnet generated $6.3 billion of total sales, in line with seasonality and our own expectations. Pro-forma sales to higher-margin Western markets (EMEA and…
Amgen (AMGN) reported second quarter 2014 earnings of $2.37 per share, well above the Consensus Estimate of $1.99 and the year-ago earnings of $1.88. Total revenues increased 11% to $5,180 million in the second quarter of 2014, beating the Consensus Estimate of $4,875 million. Including one-time items, second quarter earnings increased 22% to $2.01 per…
Ametek AME delivered first-quarter earnings of $0.51 per diluted share, an 11% increase versus the first quarter of 2012. While operating margin performance was ahead of pace to meet our full-year expectation, revenue growth, including acquisitions, of 7% was a bit weaker than we anticipated. Management increased the bottom end of its full-year EPS guidance…
